FDA Approved: DAPTOMYCIN — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

FDA approved a supplemental application for daptomycin (Hikma Pharmaceuticals USA Inc.), covering an additional formulation/strength under an ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacteremia
• Infective Endocarditis
• Skin and Soft Tissue Infections

Drugs mentioned

• Daptomycin (daptomycin)

Snippet

SUPPL AP for DAPTOMYCIN (DAPTOMYCIN)